Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- First Posted Date
- 2009-12-07
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 68
- Registration Number
- NCT01027000
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 18
- Registration Number
- NCT01020539
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 263
- Registration Number
- NCT01020734
- Locations
- 🇰🇷
Inje University - Haeundae Paik Hospital, Busan, Korea, Republic of
🇰🇷Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 38
- Registration Number
- NCT01019876
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Hematopoietic Stem Cell Transplantation Based on Pharmacokinetic and Pharmacodynamic Modeling
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01018446
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Daehangno, Jongno-gu, Korea, Republic of
Autologous Transplantation for Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT01003054
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT00990249
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study in Localized and Disseminated Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 907
- Registration Number
- NCT00987636
- Locations
- 🇩🇪
University Hopital Essen, Pediatrics III, Hematology/ Oncology, Sarcoma Centre, International Ewing Sarcoma Study Group, West German Cancer Centre, Essen, Germany
🇩🇪University Children´s Hospital, Pediatric Hematology and Oncology, Muenster, Germany
Umbilical Cord Blood Transplant for Congenital Pediatric Disorders
- Conditions
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT00950846
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT00943319
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.